Case 2 – Trabectedin as a maintenance therapy in a patient with recurrent ovarian cancer and BRCA1 germline mutation

 

Authors

  • Filippo Greco Oncology Unit, Oncology Department, ULSS 21 Regione Veneto, Legnago (Verona), Italy.
  • Paolo Piacentini Oncology Unit, Oncology Department, ULSS 21 Regione Veneto, Legnago (Verona), Italy.
  • Andrea Remo Pathology Unit, ULSS 21 Regione Veneto, Legnago (Verona), Italy.
  • Andrea Bonetti Oncology Unit, Oncology Department, ULSS 21 Regione Veneto, Legnago (Verona), Italy.
  • Gabriella Ferrandina Gynecologic Oncology Unit, Catholic University, Rome, Italy

DOI:

https://doi.org/10.19156/cbn.2016.0008

Keywords:

BRCA, recurrent ovarian cancer, trabectedin

Abstract

Treatment of patients with recurrent ovarian cancer (ROC) is complex. This case report describes the effects of a sequence of treatments in a BRCA1 mutation carrier with serous papillary poorly differentiated, platinumsensitive ROC. This consisted in primary surgery, adjuvant chemotherapy, secondary cytoreduction with Heated IntraPEritoneal Chemotherapy (HIPEC), 12 cycles of trabectedin in combination with pegylated liposomal doxorubicin (PLD) and 12 cycles of trabectedin alone, leading to complete radiological and biochemical response.

Downloads

Published

2016-03-15

How to Cite

1.
Greco F, Piacentini P, Remo A, Bonetti A, Ferrandina G. Case 2 – Trabectedin as a maintenance therapy in a patient with recurrent ovarian cancer and BRCA1 germline mutation:  . CBN [Internet]. 2016 Mar. 15 [cited 2024 Nov. 23];4(1):41-4. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/204

Issue

Section

Meet the expert